3月28日（周五），Arbutus Biopharma Corporation（ABUS）股价在盘中大涨6.70%，引起了投资者的关注。这一显著涨幅与公司最新发布的2024财年业绩报告密切相关。
根据Arbutus Biopharma公布的财报，公司2024财年净亏损为6992万美元，较上一年度减少4.02%。尽管营业收入同比下降65.99%至617万美元，但公司净亏损的收窄似乎得到了市场的积极响应。每股基本亏损为0.38美元。从资产负债表来看，公司总负债为3434万美元，资产负债比为0.04，显示出相对稳健的财务状况。
值得注意的是，Arbutus Biopharma是一家专注于开发治疗乙型肝炎（乙肝）感染患者药物的生物制药公司。公司致力于研发具有多种作用机制的候选药物组合，并在脂质纳米颗粒技术领域拥有授权。目前，有3家机构对该公司股票给出了预测，目标均价为5.33美元，最高目标价达7.00美元，这可能也是推动股价上涨的因素之一。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.